Peptide Therapy 101: How Sermorelin, BPC-157, and NAD+ Support Recovery and Longevity

"Peptide therapy" has become one of the most searched terms in wellness and regenerative medicine—but the phrase covers a remarkably wide range of compounds, from well-studied hormones to experimental research chemicals. This article focuses on three that come up often: sermorelin, BPC-157, and NAD+. The goal is to separate what evidence supports from what remains speculative.

This article is educational and is not medical advice. Some peptides discussed are investigational and not FDA-approved for the uses described. Always consult a licensed healthcare professional before starting any peptide therapy.

What Peptides Actually Are

Peptides are short chains of amino acids—shorter than proteins. Many occur naturally in the body as signaling molecules, hormones, or building blocks. Therapeutic peptides are designed to mimic, boost, or block these natural signals. Insulin is the classic example of a peptide that became a transformative medicine.

Sermorelin: Stimulating Natural Growth Hormone

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Rather than introducing growth hormone directly, it signals the pituitary to produce more of its own. It was originally FDA-approved decades ago as a diagnostic agent for growth hormone deficiency.¹

Because it works upstream—stimulating endogenous production rather than replacing it—some clinicians prefer it over direct growth hormone for certain off-label "optimization" protocols. However, robust long-term outcome data for anti-aging or performance uses is limited, and much of the enthusiasm outpaces the published evidence. Appropriate candidates are typically identified through lab work and clinical evaluation, not self-prescription.

BPC-157: The Recovery Peptide With More Questions Than Answers

BPC-157 (Body Protection Compound) is derived from a protein found in gastric juice. Animal studies suggest it may accelerate healing of tendons, ligaments, and the gut lining, and reduce inflammation.²

That animal data is genuinely interesting. The problem is that high-quality human trials are scarce. BPC-157 is not FDA-approved for any indication, and regulators have warned against "compounded" or "research-grade" peptides sold directly to consumers.³ Anyone considering it should be aware that most claims are extrapolated from animal or lab studies, not validated human research.

NAD+: The Cellular Energy Coenzyme

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for energy metabolism and DNA repair. NAD+ levels decline with age, which has driven interest in supplementation—via oral precursors (like NMN and NR) and via injections or intravenous routes.⁴

The biological rationale is strong: NAD+ is required for sirtuin activity, mitochondrial function, and cellular stress responses. That said, translating this into measurable clinical benefits in healthy humans is still an active research area. Some studies of NAD+ precursors show increases in blood NAD+ levels, but clear outcome data on longevity or energy in humans remains preliminary.⁵

Where the Science Stands

Peptide	Evidence base	Regulatory status
Sermorelin	Established for GH deficiency; limited data for "optimization"	FDA-approved (diagnostic); off-label use common
BPC-157	Promising animal data; few human trials	Not FDA-approved
NAD+	Strong biology; emerging human data on precursors	Precursors generally available; IV/injection use varies

Red Flags to Watch For

• Peptides marketed as "research chemicals" for human self-administration.
• Claims of guaranteed recovery, anti-aging, or performance results.
• Products sold without involvement of a licensed prescriber or compounding pharmacy.

The Bottom Line

Peptides are a genuinely promising area of medicine, and some—like sermorelin and NAD+ precursors—have clearer clinical footing than others. But the category is also crowded with unproven, unregulated products. The smart move is to treat peptides like any medical decision: understand the evidence, ask hard questions, and work with a qualified provider. Probably fine. Better to know.

Sources & Citations

1. Thorner MO, et al. Sermorelin (Geref) for treatment of growth hormone deficiency. Endocrine Reviews, clinical pharmacology literature.
2. Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 2016.
3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers; enforcement actions on unapproved bulk drug substances including BPC-157.
4. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science, 2015.
5. Elhassan YS, et al. Nicotinamide riboside enhances muscle mitochondrial biogenesis in humans. Science Translational Medicine, 2019.